Fluorescence In-Situ Hybridization Probe Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2024 – 2032

Fluorescence In-Situ Hybridization Probe Market Size

Fluorescence In-Situ Hybridization Probe Market size is likely to depict significant growth from 2024 to 2032 due to a noticeable rise in incidences of chronic diseases, including genetic disorders and cancer disorders. According to WHO estimates, genetic disorders and congenital abnormalities occur in nearly 2% to 5% of live births, accounting for up to 30% of pediatric hospital admissions, while leading to 50% of childhood deaths in industrialized countries.
 

The widespread usage of Fluorescence in-situ hybridization (FISH) technique in the diagnostics, encompassing the detection of structural and numerical anomalies in chromosomes, therapeutic drug monitoring, characterization of marker chromosomes, and identification of rare and genetic diseases, serve as a significant market driver.
 

Fluorescence In-Situ Hybridization Probe Market Trends

Growing R&D efforts undertaken by key players, specifically aimed at creating targeted biomarkers and innovative products further propels the industry gains. Furthermore, there is a rising awareness of the benefits linked to early detection and treatment, along with the uptick in healthcare spending and the innovation of new probes. 
 

However, the industry dynamics will be influenced by the compromised healthcare infrastructure and economic downturn resulting from the ongoing conflict between Ukraine and Russia.
 

Fluorescence In-Situ Hybridization Probe Market Analysis

Based on the type of technique, the Flow-FISH segment is anticipated to account for lucrative gains through 2032, driven by the concomitant detection of protein and RNA. This allows for the identification of cells expressing a gene while concurrently transforming it into a protein. Moreover, the widespread application of this technique as a diagnostic test for measuring telomere length in humans is poised to enhance segment share in the foreseeable future. 
 

The lung cancer segment is expected to grow at a decent pace between 2024 and 2032 attributed to the rising cases of lung cancer worldwide. As per Cancer.org, lung cancer is considered one of the leading causes, accounting for 25% of all cancer deaths globally. FISH probes identify chromosomal alterations pivotal to the advancement and evolution of lung cancer, pointing potential targets for novel anticancer drugs.
 

North America fluorescence in-situ hybridization probe market is slated to accumulate a sizeable revenue share by 2032, driven by the rising prevalence of genetic disorders and cancer in developed economies. According to reliable estimates, genetic disorders are likely to affect the lives of nearly 500,000 children in Canada. FISH probes offer high accuracy in the detection of chromosomal abnormalities leading to such disorders, bolstering the industry growth.
 

Fluorescence In-Situ Hybridization Probe Market Share

Leading players in the fluorescence in-situ hybridization probe industry include:

• PerkinElmer
• F. Hoffmann-La Roche AG
• Abnova Corporation
• Abbott Laboratories
• Biosearch Technologies

Companies operating in this industry are taking up organic strategies such as acquisitions & mergers, collaborations, and product launches to strengthen their position and amplify their profits.
 

Fluorescence In-Situ Hybridization Probe Industry News

• In October 2023, Monte Rosa Therapeutics and F. Hoffmann-La Roche AG signed a strategic partnership and licensing agreement for the discovery & development of molecular glue degraders (MGDs) to target cancer and neurological disorders.